Biotech Drug Report Generated Aug 18, 2026

RT-114

RANI·Rani Therapeutics, LLC

MIXED

Drug Impact Rating4/10

Trial Phase: Phase 1 (Phase 1a)
Time to Market: Unknown — still Phase 1; Phase 1b obesity data not expected until 2027, and a realistic approval (if trials succeed) is likely several years out.
Why 4/10: No hard, dated binary in the next ~12 months: the Phase 1a readout already passed (July 15, 2026), and the next data catalyst — a Phase 1b repeat-dose obesity study expected to begin in 2026 with data in 2027 — has no fixed date, so an early-stage program with a major-but-un-dated catalyst scores 4.

Actionable Insight ◆ MIXED

Watch for the start of the Phase 1b repeat-dose study in obesity (guided by the added Phase 1a cohort) and any dated disclosure of 2027 data — that is the next real re-rating event for the RT-114 story. Be aware the stock has been repeatedly diluted (a $20.0M offering in May 2026 at $1.07/share plus earlier private placements), so weigh share-count growth against any headline progress; insider buying by CEO Talat Imran and 10%-owner Mir Imran in July 2026 is a modest positive signal.

Price Chart

Loading chart...

Executive Summary

RT-114 is Rani Therapeutics' (Nasdaq: RANI) oral RaniPill capsule version of PG-102, a GLP-1/GLP-2 dual agonist licensed from South Korea's ProGen, aimed at obesity. Positive initial Phase 1a data (July 15, 2026) showed oral exposure exceeding a matched subcutaneous dose, validating the delivery platform but leaving the drug at the earliest clinical stage; Phase 1b obesity data is only expected in 2027. RANI is a ~$0.85 stock (52-week range $0.44–$3.87) with a heavily-diluted, small-cap profile, insider buying, a Chugai collaboration backing the balance sheet, and analyst price targets far above the market price — a speculative mixed risk/reward.

How It Works

RT-114 is a swallowable capsule (the RaniPill) that uses dissolvable microneedles to deliver a biologic drug through the intestinal wall, letting large peptide drugs be taken by mouth instead of by injection. The drug it delivers, PG-102, is a dual agonist that mimics two gut hormones: GLP-1 (which suppresses appetite and lowers blood sugar — the Ozempic/Wegovy mechanism) and GLP-2 (which supports the gut lining, potentially adding weight-loss or tolerability benefits). It is being developed for obesity.

Trial Status

Positive initial Phase 1a data announced July 15, 2026: oral RT-114 achieved systemic exposure reportedly >150% of a matched 12 mg subcutaneous dose of PG-102, with no serious adverse events and mild, transient side effects consistent with the GLP-1/GLP-2 drug class. The Phase 1a study is being expanded with an additional cohort to inform dose selection; a Phase 1b repeat-dose study in obesity patients is expected to begin in 2026 with data in 2027.

The Two-Sided Case

▲ Bull Case5

Positive Phase 1a proof-of-concept (July 15, 2026): oral RT-114 delivered systemic exposure reportedly >150% of a matched 12 mg subcutaneous PG-102 dose, with no serious adverse events — a strong signal for the RaniPill oral-delivery platform.

Insider buying in July 2026: CEO Talat Imran purchased 35,000 shares at ~$0.7198 and 10%-owner/director Mir A. Imran purchased 36,000 shares at ~$0.69 (open-market, per Form 4 filings).

Analyst consensus is bullish (7 Buy + 2 Strong Buy vs 1 Hold as of Aug 2026) with a mean price target of $7.50 (4 analysts, range $5–$11) versus a ~$0.80 price — roughly 7x implied upside; Canaccord Genuity maintained Buy in May 2026.

Balance sheet strengthened: Q1 2026 cash of $43.4M expected to fund operations into Q4 2027, supported by a Chugai collaboration (up to $1.085B reported) and contract revenue of $1.7M in Q1 2026 (vs $0.2M a year earlier).

Obesity is the hottest commercial category in biotech, and an oral (needle-free) GLP-1/GLP-2 dual agonist with demonstrated oral bioavailability has clear differentiation potential.

▼ Bear Case6

Drug is only in Phase 1 — Phase 1a is a tiny single-dose study; most Phase 1 molecules fail, and the next meaningful readout (Phase 1b obesity data) is not expected until 2027, so there is no near-term binary to de-risk the thesis.

Chronic dilution: a $20.0M registered direct offering priced May 26, 2026 at $1.07/share plus pre-funded warrants, following a reported $60.3M private placement and an earlier 2025 capital raise — share count keeps growing ahead of any revenue.

Elevated bearish positioning: FINRA daily short-volume ratio ~0.52 over 58 sessions (i.e., over half of recent volume was short-sale execution flow) and ~8.46M shares short as of the 7/31/2026 settlement (≈6.83% of estimated shares outstanding, days-to-cover ~6.9).

Fierce competition in oral obesity drugs from far larger players (oral semaglutide, orforglipron-class candidates) that already have Phase 3 data or approved products — a Phase 1 oral agonist faces a huge efficacy/tolerability bar.

Micro-cap execution risk: CFO transition announced in Q1 2026 (new CFO appointed June 29, 2026), near-zero revenue, and heavy dependence on partnership milestone payments; the SecBot bull/bear evidence checklist net signal is currently neutral.

SecBot's local evidence checklist shows several large managers trimming or exiting (e.g., Squarepoint near-exit -95.2%, Qube trim -67.9% in 2026-Q1), offsetting the accumulation signals.

Upcoming Catalysts

Expansion cohort of the ongoing Phase 1a study of RT-114 (results to guide dose selection — no fixed date)
Initiation of the Phase 1b repeat-dose study in obesity patients (guided to begin in 2026)
Phase 1b obesity data (expected 2027 — the key re-rating event)
Potential Chugai collaboration milestone payment supporting cash runway into Q4 2027
Quarterly financial reports and any further capital raises

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Rani Therapeutics, LLC Press Release RANI ·Originating report

Sources · 8

Hover a chip for the title

1 globenewswire.com2 globenewswire.com3 globenewswire.com4 globenewswire.com5 globenewswire.com6 sec.gov7 sec.gov8 sec.gov